Javascript must be enabled to continue!
Symptomatic Crystalluria Associated with Indinavir
View through CrossRef
OBJECTIVE:
To report a case of severe and recurrent crystalluria resulting from the use of indinavir and to review the literature describing this adverse effect.
CASE SUMMARY:
A 26-year-old HIV-positive white woman had recurrent episodes of left-sided flank pain accompanied by dilation of the left renal collecting system while undergoing treatment with a triple-drug regimen including indinavir 1200 mg every 12 hours (full dosage). Typical indinavir crystalluria was observed, with no evidence of stones. Acute episodes were treated with intravenous fluids, diclofenac, and ciprofloxacin. Crystalluria and clinical symptoms eventually resolved with withdrawal of indinavir and substitution with a different protease inhibitor. Renal function remained normal.
DISCUSSION:
A wide spectrum of disorders of the urinary tract can occur in subjects taking indinavir, with potentially severe complications caused by crystalluria and stones. Indinavir is excreted in the urine; the low solubility of those crystals is the critical factor accounting for the risk of stone formation. An elevated pH with a reduced excretion of citric acid contributes to the low urinary solubility of indinavir. Pharmacokinetic interactions with other drugs, leading to elevated plasma concentrations of indinavir, and dehydration could also increase the risk of stone formation. The impact on renal function can be unfavorable over the long-term period. Cornerstones of treatment and prevention are increased fluid intake and possibly urinary acidification. Emergency drainage may be required for patients with severe obstruction. Reducing the dosage of indinavir has been proposed, but this carries the risk of viral mutations with development of resistance.
CONCLUSIONS:
Treatment with indinavir can result in crystalluria with potentially severe obstruction. All patients taking indinavir, not only those with documented crystalluria or renal effects from the drug, should greatly increase their fluid intake and have renal function checked at baseline and then monitored regularly. Urinalysis also should be performed regularly for appropriate monitoring and prevention.
SAGE Publications
Title: Symptomatic Crystalluria Associated with Indinavir
Description:
OBJECTIVE:
To report a case of severe and recurrent crystalluria resulting from the use of indinavir and to review the literature describing this adverse effect.
CASE SUMMARY:
A 26-year-old HIV-positive white woman had recurrent episodes of left-sided flank pain accompanied by dilation of the left renal collecting system while undergoing treatment with a triple-drug regimen including indinavir 1200 mg every 12 hours (full dosage).
Typical indinavir crystalluria was observed, with no evidence of stones.
Acute episodes were treated with intravenous fluids, diclofenac, and ciprofloxacin.
Crystalluria and clinical symptoms eventually resolved with withdrawal of indinavir and substitution with a different protease inhibitor.
Renal function remained normal.
DISCUSSION:
A wide spectrum of disorders of the urinary tract can occur in subjects taking indinavir, with potentially severe complications caused by crystalluria and stones.
Indinavir is excreted in the urine; the low solubility of those crystals is the critical factor accounting for the risk of stone formation.
An elevated pH with a reduced excretion of citric acid contributes to the low urinary solubility of indinavir.
Pharmacokinetic interactions with other drugs, leading to elevated plasma concentrations of indinavir, and dehydration could also increase the risk of stone formation.
The impact on renal function can be unfavorable over the long-term period.
Cornerstones of treatment and prevention are increased fluid intake and possibly urinary acidification.
Emergency drainage may be required for patients with severe obstruction.
Reducing the dosage of indinavir has been proposed, but this carries the risk of viral mutations with development of resistance.
CONCLUSIONS:
Treatment with indinavir can result in crystalluria with potentially severe obstruction.
All patients taking indinavir, not only those with documented crystalluria or renal effects from the drug, should greatly increase their fluid intake and have renal function checked at baseline and then monitored regularly.
Urinalysis also should be performed regularly for appropriate monitoring and prevention.
Related Results
A Pharmacokinetic Drug-Drug Interaction Study of Venlafaxine and Indinavir
A Pharmacokinetic Drug-Drug Interaction Study of Venlafaxine and Indinavir
Depression is a common occurrence in the human immunodeficiency virus (HIV)-infected population. Complications in treating depressed HIV-infected individuals include the use of mul...
Investigation of Crystalluria and Its Association with Urinary Tract Infections
Investigation of Crystalluria and Its Association with Urinary Tract Infections
Background: Crystalluria, the presence of crystals in urine, can arise from factors such as dehydration, dietary habits, and metabolic disorders, often linked to urinary tract infe...
Bioequivalence of indinavir capsules in healthy volunteers
Bioequivalence of indinavir capsules in healthy volunteers
Background: Indinavir, one component in the HAART regimen, plays an important role in the current treatment of HIV-infection and AIDS. Availability and accessibility of qualified g...
Summaries, Analysis and Simulations of Recent COVID-19 Epidemic in Mainland China During December 31 2021-December 6 2022
Summaries, Analysis and Simulations of Recent COVID-19 Epidemic in Mainland China During December 31 2021-December 6 2022
AbstractBackgroundThe recent COVID-19 epidemic in mainland China is an important issue for studying the prevention and disease control measures and the spread of the COVID-19 epide...
Calcium Oxalate Crystallization-Modifying Activity of Moringa oleifera Seeds-Derived Thiocarbamates: In vitro and In vivo Evaluation
Calcium Oxalate Crystallization-Modifying Activity of Moringa oleifera Seeds-Derived Thiocarbamates: In vitro and In vivo Evaluation
Abstract
Calcium oxalate (CaOx) is the predominant crystalline component of most urinary stones. Formation of kidney stones affects approximately...
Crystalluria
Crystalluria
Abstract
Crystalluria is a marker of urine supersaturation with substances deriving from metabolic disorders, inherited diseases or drugs. The investigation of cr...
Sulfamethoxazole-induced crystal nephropathy: characterization and prognosis in a case series
Sulfamethoxazole-induced crystal nephropathy: characterization and prognosis in a case series
AbstractCotrimoxazole (Trimethoprim/Sulfamethoxazole-SMX) is frequently used in critically ill and immunocompromised patients. SMX is converted to N-acetyl-sulfamethoxazole (NASM) ...
Prognostic impact of natriuretic peptide value in patients with symptomatic and asymptomatic severe aortic stenosis
Prognostic impact of natriuretic peptide value in patients with symptomatic and asymptomatic severe aortic stenosis
Abstract
Background
There is a scarcity of data on the prognostic value of natriuretic peptide (NP) in either symptomatic...

